SG Americas Securities LLC reduced its position in shares of Envista Holdings Co. (NYSE:NVST - Free Report) by 63.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 15,629 shares of the company's stock after selling 26,673 shares during the period. SG Americas Securities LLC's holdings in Envista were worth $301,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in the company. Pacer Advisors Inc. raised its stake in shares of Envista by 22.2% during the third quarter. Pacer Advisors Inc. now owns 3,529,827 shares of the company's stock worth $69,749,000 after buying an additional 642,401 shares during the last quarter. Diamond Hill Capital Management Inc. grew its holdings in Envista by 8.1% during the third quarter. Diamond Hill Capital Management Inc. now owns 1,335,710 shares of the company's stock valued at $26,394,000 after purchasing an additional 100,360 shares during the period. Harbor Capital Advisors Inc. grew its holdings in Envista by 138.5% during the third quarter. Harbor Capital Advisors Inc. now owns 404,589 shares of the company's stock valued at $7,995,000 after purchasing an additional 234,941 shares during the period. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Envista during the fourth quarter valued at approximately $53,000. Finally, Hotchkis & Wiley Capital Management LLC acquired a new position in Envista during the third quarter valued at approximately $14,965,000.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on NVST. Stifel Nicolaus boosted their price objective on shares of Envista from $18.00 to $21.00 and gave the company a "buy" rating in a report on Wednesday, October 23rd. Mizuho initiated coverage on shares of Envista in a report on Wednesday, December 4th. They issued an "underperform" rating and a $20.00 price target for the company. Needham & Company LLC reiterated a "hold" rating on shares of Envista in a report on Thursday. Piper Sandler upped their price target on shares of Envista from $17.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, February 3rd. Finally, Leerink Partners upgraded shares of Envista from an "underperform" rating to a "market perform" rating and upped their price target for the company from $16.00 to $23.00 in a report on Thursday, October 31st. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $20.21.
Check Out Our Latest Report on NVST
Envista Stock Performance
Shares of NVST stock traded down $0.53 on Friday, hitting $21.27. The company's stock had a trading volume of 2,438,400 shares, compared to its average volume of 2,268,009. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.77 and a current ratio of 2.04. The stock's 50 day moving average is $19.94 and its 200-day moving average is $19.17. Envista Holdings Co. has a fifty-two week low of $15.15 and a fifty-two week high of $23.06. The company has a market capitalization of $3.66 billion, a PE ratio of -3.28, a PEG ratio of 2.06 and a beta of 1.34.
Envista (NYSE:NVST - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. Equities research analysts expect that Envista Holdings Co. will post 1.06 earnings per share for the current fiscal year.
About Envista
(
Free Report)
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
See Also
Before you consider Envista, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Envista wasn't on the list.
While Envista currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
